 帝京大学薬学部 |
研究室ページ | English | |
| 薬物動態学研究室 | ||
|
|
||
 |
論文リスト | |
1. |
Elucidating the roles of TM7SF3 and LHFPL6 in the putative H+/OC antiporter function in the human brain capillary endothelial cell line, hCMEC/D3. Svane N, Kurosawa T, Schmid B, Saaby L, Kristensen M, Tabata H, Kubo Y, Terasaki T, Brodin B, Deguchi Y. Eur J Pharm Sci. 217:107409 (2026). | |
2. |
Expression and Functional Evaluation of ABC and SLC Transporters in Human Choroid Plexus Papilloma (HIBCPP) Cells: A Human Blood-Cerebrospinal Fluid Barrier Model. Kurosawa T, Ohtsuki S, Ishikawa H, Schroten H, Schwerk C, Kubo Y, Deguchi Y. Pharm Res. 43:137-147 (2026). | |
|
3.
|
Brain distribution and muscarinic receptor occupancy of an active metabolite of fesoterodine in rats; Mizuki Shiho, Shimako Tanaka, Eriko Nakatani, Toshiki Kurosawa, Yoshiyuki Kubo, Yoshiharu Deguchi, Takashi Okura; J. Pharmacol. Exp. Ther., 392(2):100058 (2025) | |
|
4.
|
Involvement of Proton-Coupled Organic Cation Antiporter in Human Blood?Brain Barrier Transport of Mesoridazine and Metoclopramide; Yasuyuki Debori, Tomoko Igari, Masanori Nakakariya, Hideki Hirabayashi, Kazunobu Aoyama, Nobuyuki Amano, Toshiki Kurosawa, Yoshiyuki Kubo, Yoshiharu Deguchi; Biol. Pharm. Bull., 47(10):1662-1667 (2024) | |
|
5.
|
Blood-to-testis transport of ribavirin involves carrier-mediated processes at the blood-testis barrier; Ito T, Kubo Y, Tega Y, Akanuma SI, Hosoya KI; J. Pharm. Sci., in press (2024) | |
|
6.
|
Development and Functional Evaluation of MDR1-Expressing Microvascular Endothelial-Like Cells Derived from Human iPS Cells as an In Vitro Blood-Brain Barrier Model; Yamaguchi T, Sako D, Kurosawa T, Nishijima M, Miyano A, Kubo Y, Ohtsuki S, Kawabata K, Deguchi Y; J. Pharm. Sci., 112:3216-3223 (2023) | |
|
7.
|
Characterization of LysoTracker Red uptake by in vitro model cells of the outer blood-retinal barrier: Implication of lysosomal trapping with cytoplasmic vacuolation and cytotoxicity; Tega Y, Takeuchi T, Nagano M, Makino R, Kubo Y, Akanuma SI, Hosoya KI; Drug Metab. Pharmacokinet., 51:100510 (2023) | |
|
8.
|
Carrier-Mediated Process of Putrescine Elimination at the Rat Blood-Retinal Barrier; Tega Y, Kubo Y, Miura H, Ri K, Tomise A, Akanuma SI, Hosoya KI; Int. J. Mol. Sci., 24(10):9003 (2023) | |
|
9.
|
Proteomics-Based Transporter Identification by the PICK Method: Involvement of TM7SF3 and LHFPL6 in Proton-Coupled Organic Cation Antiport at the Blood-Brain Barrier; Toshiki Kurosawa, Yuma Tega, Yasuo Uchida, Kei Higuchi, Hidetsugu Tabata, Takaaki Sumiyoshi, Yoshiyuki Kubo, Tetsuya Terasaki, Yoshiharu Deguchi; Pharmaceutics, 14(8), 1683 (2022) | |
|
10.
|
Functional characteristics of 3'-azido-3'-deoxythymidine transport at the blood-testis barrier; Takeru Ito, Yoshiyuki Kubo, Shin-Ichi Akanuma, Ken-Ichi Hosoya; Int. J. Pharm., 625:122044 (2022) | |
|
11.
|
Naltrexone Transport by a Proton-Coupled Organic Cation Antiporter in hCMEC/D3 Cells, an in Vitro Human Blood-Brain Barrier Model; Atsushi Kitamura, Kei Higuchi, Toshiki Kurosawa, Takashi Okura, Yoshiyuki Kubo, Yoshiharu Deguchi; Biol. Pharm. Bull., 45(10), 1585-1589 (2022) | |
|
12.
|
Construction and Functional Evaluation of a Three-Dimensional Blood–Brain Barrier Model Equipped With Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells.; Toshiki Kurosawa, Daiki Sako, Yuma Tega, Yasuyuki Debori, Yumi Tomihara, Kazunobu Aoyama, Yoshiyuki Kubo, Nobuyuki Amano, Yoshiharu Deguchi.; Pharm Res. Online ahead of print. (2022) | |
|
13.
|
Involvement of TauT/SLC6A6 in Taurine Transport at the Blood-Testis Barrier.; Yoshiyuki Kubo, Sakiko Ishizuka, Takeru Ito, Daisuke Yoneyama, Shin-Ichi Akanuma, Ken-Ichi Hosoya.; Metabolites. 12(1):66. (2022) | |
14. |
Uptake Study in Lysosome-Enriched Fraction: Critical Involvement of Lysosomal Trapping in Quinacrine Uptake but Not Fluorescence-Labeled Verapamil Transport at Blood-Retinal Barrier. Kubo Y, Yamada M, Konakawa S, Akanuma S, Hosoya K. Pharmaceutics. 12:747 (2020). | |
15. |
Riboflavin transport mediated by riboflavin transporters (RFVTs/SLC52A) at the rat outer blood-retinal barrier. Kubo Y, Miki S, Akanuma S, Hosoya K. Drug Metab Pharmacokinet. 34:380-386 (2019). | |
|
16.
|
Impact of Nicotine Transport across the Blood-Brain Barrier: Carrier-Mediated Transport of Nicotine and Interaction with Central Nervous System Drugs; Tega Y, Yamazaki Y, Akanuma SI, Kubo Y, and Hosoya KI.; Biol Pharm Bull., 41(9),1330-1336 (2018) | |
17. |
Blood-to-Retina Transport of Fluorescence-Labeled Verapamil at the Blood-Retinal Barrier. Kubo Y, Nakazawa A, Akanuma S, Hosoya K. Pharm Res. 2018 Mar 12;35(5):93 (2018). | |
18. |
Inner Blood-Retinal Barrier Dominantly Expresses Breast Cancer Resistance Protein: Comparative Quantitative Targeted Absolute Proteomics Study of CNS Barriers in Pig. Zhang Z, Uchida Y, Hirano S, Ando D, Kubo Y, Auriola S, Akanuma SI, Hosoya KI, Urtti A, Terasaki T, Tachikawa M. Mol Pharm. 14:3729-3738 (2017). | |
19. |
Retina-to-Blood Transport of 1-Methyl-4-Phenylpyridinium Involves Carrier-Mediated Process at the Blood-Retinal Barrier. Kubo Y, Yamamoto M, Matsunaga K, Usui T, Akanuma SI, Hosoya KI. J Pharm Sci. 106:2583-2591 (2017). | |
20. |
Blood-to-retina transport of riboflavin via RFVTs at the inner blood-retinal barrier. Kubo Y, Yahata S, Miki S, Akanuma SI, Hosoya KI. Drug Metab Pharmacokinet. 32:92-99 (2017). | |
|
21.
|
Functional expression of nicotine influx transporter in A549 human alveolar epithelial cells. Tega Y, Yuzurihara C, Kubo Y, Akanuma SI, Ehrhardt C, Hosoya KI. Drug Metab. Pharmacokinet., 31(1), 99-101(2016) |
|
|
22.
|
Histamine elimination from the cerebrospinal fluid across the blood-cerebrospinal fluid barrier . Involvement of plasma membrane monoamine transporter (PMAT/SLC29A4). Usui T, Nakazawa A, Okura T, Deguchi, Y, Akanuma SI, Kubo Y, Hosoya K; J Neurochem. 139, 408 ? 418 (2016) | |
23. |
Lysosomal Trapping Is Present in Retinal Capillary Endothelial Cells: Insight into Its Influence on Cationic Drug Transport at the Inner Blood-Retinal Barrier. Kubo Y, Seko N, Usui T, Akanuma S, Hosoya K. Biol Pharm Bull. 39:1319-24 (2016). | |
|
24.
|
Involvement of the H+/organic cation antiporter in nicotine transport in rat liver. Tega Y, Akanuma S, Kubo Y, Hosoya K. Drug Metab. Dispos., 43(1), 89-92 (2015) | |
|
25.
|
Carrier-Mediated Transport of Nicotine Across the Inner Blood-Retinal Barrier: Involvement of a Novel Organic Cation Transporter Driven by an Outward H(+) Gradient. Tega Y, Kubo Y, Yuzurihara C, Akanuma S, Hosoya K. J. Pharm. Sci., 104(9), 3069-3075 (2015) | |
26. |
Impact of Cationic Amino Acid Transporter 1 on Blood-Retinal Barrier Transport of L-Ornithine. Kubo Y, Obata A, Akanuma S, Hosoya K. Invest Ophthalmol Vis Sci. 56:5925-32 (2015). | |
27. |
Quantitative Determination of Luminal and Abluminal Membrane Distributions of Transporters in Porcine Brain Capillaries by Plasma Membrane Fractionation and Quantitative Targeted Proteomics. Kubo Y, Ohtsuki S, Uchida Y, Terasaki T. J Pharm Sci. 104:3060-8 (2015). | |
28. |
Involvement of carrier-mediated transport in the retinal uptake of clonidine at the inner blood-retinal barrier. Kubo Y, Tsuchiyama A, Shimizu Y, Akanuma S, Hosoya K. Mol Pharm. 11:3747-53 (2014). | |
29. |
Involvement of the carrier-mediated process in the retina-to-blood transport of spermine at the inner blood-retinal barrier. Kubo Y, Tomise A, Tsuchiyama A, Akanuma S, Hosoya K. Exp Eye Res. 124:17-23 (2014). | |
30. |
Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter. Kubo Y, Shimizu Y, Kusagawa Y, Akanuma S, Hosoya K. J Pharm Sci. 102:3332-42 (2013). | |
31. |
Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier. Kubo Y, Kusagawa Y, Tachikawa M, Akanuma S, Hosoya K. Pharm Res. 30:847-56 (2013). | |
32. |
Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood-brain barrier model. Ohtsuki S, Ikeda C, Uchida Y, Sakamoto Y, Miller F, Glacial F, Decleves X, Scherrmann JM, Couraud PO, Kubo Y, Tachikawa M, Terasaki T. Mol Pharm. 10:289-96 (2013). | |
|
33.
|
Blood-to-brain influx transport of nicotine at the rat blood-brain barrier: involvement of a pyrilamine-sensitive organic cation transport process. Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. Neurochem. Int., 62(2), 173-81 (2012) |
|
34. |
Application of membrane permeability evaluated in in vitro analyses to estimate blood-retinal barrier permeability. Kubo Y, Fukui E, Akanuma S, Tachikawa M, Hosoya K. J Pharm Sci. 101:2596-605 (2012). | |
35. |
Function and regulation of taurine transport in Muller cells under osmotic stress. Ando D, Kubo Y, Akanuma S, Yoneyama D, Tachikawa M, Hosoya K. Neurochem Int. 60:597-604 (2012). | |
36. |
Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A. Pharm Res. 27:832-40 (2010). | |
37. |
Sodium-coupled electrogenic transport of pyroglutamate (5-oxoproline) via SLC5A8, a monocarboxylate transporter. Miyauchi S, Gopal E, Babu E, Srinivas SR, Kubo Y, Umapathy NS, Thakkar SV, Ganapathy V, Prasad PD. Biochim Biophys Acta. 1798:1164-71 (2010). | |
|
38.
|
Genetic deficiency of carnitine/organic cation transporter2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice; Sayaka Kato, Yukio Kato, Tadakatsu Nakamura, Tomoko Sugiura, Yoshiyuki Kubo, Yoshiharu Deguchi, and Akira Tsuji; Bio. Drug Dispos., 39, 495-507 (2009). | |
39. |
ABCA5 resides in lysosomes, and ABCA5 knockout mice develop lysosomal disease-like symptoms. Kubo Y, Sekiya S, Ohigashi M, Takenaka C, Tamura K, Nada S, Nishi T, Yamamoto A, Yamaguchi A. Mol Cell Biol. 25:4138-49 (2005). | |
40. |
Cloning of rat ABCA7 and its preferential expression in platelets. Sasaki M, Shoji A, Kubo Y, Nada S, Yamaguchi A. Biochem Biophys Res Commun. 304:777-82 (2003). | |
41. |
Monoclonal antibody that binds to the central loop of the Tn10-encoded metal tetracycline/H+ antiporter of Escherichia coli.Nada S, Murakami S, Okamoto S, Kubo Y, Yamaguchi A. J Biochem. 129:87-91 (2001). | |
42. |
Cysteine-scanning mutagenesis around transmembrane segments 1 and 11 and their flanking loop regions of Tn10-encoded metal-Tetracycline/H+ antiporter. Kimura-Someya T, Iwaki S, Konishi S, Tamura N, Kubo Y, Yamaguchi A. J Biol Chem. 275:18692-7 (2000). | |
43. |
Proximity of periplasmic loops in the metal-Tetracycline/H(+) antiporter of Escherichia coli observed on site-directed chemical cross-linking. Kubo Y, Konishi S, Kawabe T, Nada S, Yamaguchi A. J Biol Chem. 275:5270-4 (2000). | |
|
著書リスト・その他 | |
|
1.
|
Human Cerebrospinal Fluid and Cerebrovascular Barrier; Part III, chapter 14 "Construction and Functional Evaluation of 2D and 3D Human Blood?Brain Barrier Models"; Toshiki Kurosawa, Yoshiyuki Kubo, Yoshiharu Deguchi; Springer Singapore (2025) | |
|
2.
|
分担執筆 久保義行、出口芳春； エピソード 薬物動態学 第2版 TSUJI's PHARMACOKINETICS -薬物動態学の解明-； 京都廣川書店 (2023) | |
3. |
Kubo Y, Akanuma S, Hosoya K. In vivo analysis to study transport across the blood-retinal barrier. ‘Barichello T / Springer Protocols, Blood-Brain Barrier, Neuromethods 142’. 249-265. Humana Press (2019) | |
4. |
久保義行. 蛍光標識体を用いた血液組織関門輸送機構の解明. ‘ファルマシア’. 55 (12) 1145-1149 (2019). | |
5. |
Akanuma S, Kubo Y, Hosoya K. Techniques for evaluating efflux transport of radiolabeled drugs and compounds from the cerebrospinal fluid across the blood-cerebrospinal fluid barrier. ‘Barichello T / Springer Protocols, Blood-Brain Barrier, Neuromethods 142’. 231-248. Humana Press (2019) | |
6. |
Recent advances in drug and nutrient transport across the blood-retinal barrier. Kubo Y, Akanuma S, Hosoya K. Expert Opin Drug Metab Toxicol. 14:513-531 (2018). | |
7. |
久保義行, 細谷健一. 血液網膜関門における網膜への薬物輸送メカニズム. ‘PHARM STAGE (技術情報協会)’. 17(1) 73-79 (2017). | |
8. |
Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Kubo Y, Akanuma S, Hosoya K. Biol Pharm Bull. 40:1139-1145 (2017). | |
9. |
Impact of SLC6A Transporters in Physiological Taurine Transport at the Blood-Retinal Barrier and in the Liver. Kubo Y, Akanuma S, Hosoya K. Biol Pharm Bull. 39:1903-1911 (2016). | |
10. |
久保義行. 血液組織関門におけるカチオン性薬物輸送機構の解明. ‘薬学雑誌’. 135 (10) 1135-40 (2015). | |
11. |
Kubo Y, Akanuma S and Hosoya K. The blood-retinal barrier and carnosine. ‘Preedy V / Imidazole Dipeptides: Chemistry, Analysis, Function, and Effects’. 528-547. The Royal Society of Chemistry/ ELSEVIER, NED (2015). | |
12. |
久保義行.「血液網膜関門におけるカチオン輸送機構の研究：トランスポーターの道を巡って」. 薬剤学. 75 (5) 296-300 (2015) | |
13. |
Kubo Y, Kato Y, Tsuji A. Experimental approaches to study drug transporters. ‘You G / Morris, ME / Drug Transporters 2nd edition. 355-369. Wiley (2014) | |
14. |
Hosoya K and Kubo Y. Vitamin transport across the blood-retinal barrier: focus on vitamins C, E and biotin. ‘Preedy, VR / Handbook of Diet, Nutrition and the Eye 1st edition’. 321-329. Academic Press/ELSEVIER, NED (2014) | |
15. |
久保義行, 赤沼伸乙, 細谷健一. カチオン性薬物輸送に見る血液網膜関門と血液脳膜関門の類似と相違. ‘寺崎哲也編集 血液脳関門: BBBの概念提唱から百年の時を越えて捉えたその実体’. 細胞工学. 32 (9) 950-4学研メディカル秀潤社 (2013) | |
16. |
久保義行, 赤沼伸乙, 細谷健一. 血液網膜関門の機能特性を利用したドラッグデリバリー. ‘楠原洋之編集 トランスポーターを利用したドラッグデリバリー’. Drug Delivery System. 27(5) 361-9(2012) | |
17. |
Quantitative targeted absolute proteomics-based ADME research as a new path to drug discovery and development: methodology, advantages, strategy, and prospects. Ohtsuki S, Uchida Y, Kubo Y, Terasaki T. J Pharm Sci. 100:3547-59 (2011). | |
18. |
寺崎哲也, 大槻純男, 久保義行, 内田康雄, 大峰 健. 定量的トランスポーター解析のための質量分析による膜タンパク質絶対定量法. 「金井好克ら編著 トランスポートソームの世界」. 405-10. 京都廣川書店 (2011) | |
19. |
久保義行. OCTNs欠損マウスの発見・作成およびその特徴. 「辻彰監修 トランスポーター科学最前線」. 47-49. 京都廣川書店 (2008) | |
20. |
久保義行, 加藤将夫, 辻 彰. 生体外異物の取り込みと排出の分子シンクロナイゼーション. 「本宮達也 監修, 赤池敏宏, 岡本秀穂, 白井汪芳 編集“ファイバー”スーパーバイオミメティックス：近未来の新技術創成」. 447-452. NTS出版 (2006) | |
21. |
久保義行, 辻 彰. SLCトランスポーターのSNP解析とその機能変動. ゲノム医学. 4 (5): 501-507. メディカルレビュー社 (2004) | |
|
|
||